vCJD transfusion-associated Fourth Case UK

My Photo
Name:
Location: BACLIFF, Texas, United States

My mother was murdered by what I call corporate and political homicide i.e. FOR PROFIT! she died from a rare phenotype of CJD i.e. the Heidenhain Variant of Creutzfeldt Jakob Disease i.e. sporadic, simply meaning from unknown route and source. I have simply been trying to validate her death DOD 12/14/97 with the truth. There is a route, and there is a source. There are many here in the USA. WE must make CJD and all human TSE, of all age groups 'reportable' Nationally and Internationally, with a written CJD questionnaire asking real questions pertaining to route and source of this agent. Friendly fire has the potential to play a huge role in the continued transmission of this agent via the medical, dental, and surgical arena. We must not flounder any longer. ...TSS

Tuesday, August 26, 2014

Blood reference materials from macaques infected with variant Creutzfeldt-Jakob disease agent

Blood reference materials from macaques infected with variant Creutzfeldt-Jakob disease agent

Authors




  • This article reflects the views of the authors and should not be construed to represent FDA's views or policies.
  • This work was supported by the US Food and Drug Administration and by an award from the FDA Office of the Chief Scientist. Part of this work was also funded by a grant from the Alliance BioSecure Foundation.

Abstract

Background

Variant Creutzfeldt-Jakob disease (vCJD) is a fatal neurodegenerative infection that can be transmitted by blood and blood products from donors in the latent phase of the disease. Currently, there is no validated antemortem vCJD blood screening test. Several blood tests are under development. Any useful test must be validated with disease-relevant blood reference panels.

Study Design and Methods

To generate blood reference materials, we infected four cynomolgus macaques with macaque-adapted vCJD brain homogenates. Blood was collected throughout the preclinical and clinical phases of infection. In parallel, equivalent blood was collected from one uninfected macaque. For each blood collection, an aliquot was stored as whole blood and the remainder was separated into components. Aliquots of plasma from terminally ill macaques were assayed for the presence of PrPTSE with the protein misfolding cyclic amplification (PMCA) method. Infectivity of the macaque brain homogenate used to infect macaques was titrated in C57BL/6 and RIII J/S inbred wild-type mice.

Results

We sampled blood 19 times from the inoculated monkeys at various stages of the disease over a period of 29 months, generating liters of vCJD-infected macaque blood. vCJD was confirmed in all inoculated macaques. After PMCA, PrPTSE was detected in plasma from infected monkeys, but not from uninfected animals. Both mouse models were more sensitive to infection with macaque-adapted vCJD agent than to primary human vCJD agent.

Conclusion

The macaque vCJD blood panels generated in this study provide a unique resource to support vCJD assay development and to characterize vCJD infectivity in blood.
http://onlinelibrary.wiley.com/enhanced/doi/10.1111/trf.12841/
Reason For Recall Blood product, collected from a donor who was at risk for variant Creutzfeldt-Jakob disease (vCJD), was distributed.
 
Voluntary / Mandated Voluntary: Firm Initiated
Recall Initiation Date 2014-05-16
Initial Firm Notification of Consignee or Public E-Mail
Distribution Pattern Switzerland
 
 
 
see more ;
 
Biologics Red Blood Cells Leukocytes Reduced W089813410351; Class II Blood products, collected from a donor who was at risk for variant Creutzfeldt-Jakob disease (vCJD), were distributed. Inova Health Care Services, Inova Blood Donor Services
Biologics Blood and Blood Products for Reprocessing W089813410351; Class III Blood products, collected from a donor who was at risk for variant Creutzfeldt-Jakob disease (vCJD), were distributed. Inova Health Care Services, Inova Blood Donor Services
Biologics Cryoprecipitated AHF W089813410351; Class II Blood products, collected from a donor who was at risk for variant Creutzfeldt-Jakob disease (vCJD), were distributed. Inova Health Care Services, Inova Blood Donor Services
Biologics Red Blood Cells Leukocytes Reduced W088414515528; W088414516606; Class II Blood products, collected from a donor who was at risk for variant Creutzfeldt-Jakob disease (vCJD), were distributed. Blood Bank Of Hawaii
 
 
 
 
Saturday, July 07, 2012

Class II, Blood products, collected from a donor who was at risk for variant Creutzfeldt-Jakob disease ( vCJD) USA

Enforcement Report

http://vcjdtransfusion.blogspot.com/2012/07/class-ii-blood-products-collected-from.html

Monday, June 11, 2012

Guidance for Industry Draft Guidance for Industry: Amendment to “Guidance for Industry: Revised Preventive Measures to Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease and Variant Creutzfeldt-Jakob Disease by Blood and Blood Products”

IN SHORT ;

“However, based on animal studies, as well as on FDA risk assessments, the possibility of vCJD transmission by a U.S.-licensed plasma derivative, while extremely small, cannot be absolutely ruled out. For these reasons, the recommendations for labeling for plasma derivatives will include mention of vCJD for the first time, and the potential risk for its transmission. The recommended elements of the warning label for CJD are unchanged and continue to describe its transmission as a theoretical risk, given that there is no confirmed evidence that CJD is transmitted by blood (Refs. 4-7).“

IN FULL, as follows ;

Monday, June 11, 2012

Guidance for Industry Draft Guidance for Industry: Amendment to “Guidance for Industry: Revised Preventive Measures to Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease and Variant Creutzfeldt-Jakob Disease by Blood and Blood Products”

http://creutzfeldt-jakob-disease.blogspot.com/2012/06/guidance-for-industry-draft-guidance.html

Friday, June 29, 2012

Highly Efficient Prion Transmission by Blood Transfusion

http://transmissiblespongiformencephalopathy.blogspot.com/2012/06/highly-efficient-prion-transmission-by.html

Sunday, June 3, 2012

A new neurological disease in primates inoculated with prion-infected blood or blood components

http://transmissiblespongiformencephalopathy.blogspot.com/2012/06/new-neurological-disease-in-primates.html
 
Sunday, March 09, 2014
 
A Creutzfeldt-Jakob Disease (CJD) Lookback Study: Assessing the Risk of Blood Borne Transmission of Classic Forms of Creutzfeldt-Jakob Disease
 
FDA TSEAC CIRCUS AND TRAVELING ROAD SHOW FOR THE TSE PRION DISEASES
 
 
Sunday, April 06, 2014
 
SPORADIC CJD and the potential for zoonotic transmission there from, either directly or indirectly via friendly fire iatrogenic mode, evidence to date
 
 
Wednesday, December 11, 2013
 
*** Detection of Infectivity in Blood of Persons with Variant and Sporadic Creutzfeldt-Jakob Disease ***
 
 
Friday, January 10, 2014
 
vpspr, sgss, sffi, TSE, an iatrogenic by-product of gss, ffi, familial type prion disease, what it ???
 
 
Monday, May 19, 2014
 
Variant CJD: 18 years of research and surveillance
 
 
Sunday, June 29, 2014
 
Transmissible Spongiform Encephalopathy TSE Prion Disease North America 2014
 
 
Tuesday, August 12, 2014
 
*** MAD COW USDA TSE PRION COVER UP or JUST IGNORANCE, for the record AUGUST 2014 ***
 
see history of record of either the biggest cover up of mad cow disease, or one of the biggest blunders of the mad cow debacle, just my opinion of the facts...tss
 
 
Monday, June 02, 2014
 
*** Confirmed Human BSE aka mad cow Variant CJD vCJD or nvCJD Case in Texas
 
 
Tuesday, April 01, 2014
 
*** Questions linger in U.S. CJD cases 2005, and still do in 2014 ***
 
 
Monday, August 18, 2014
 
*** Barriers to Creutzfeldt-Jakob Disease Autopsies, California and the USA
 
 
PLEASE REMEMBER ;
 
The Akron, Ohio-based CJD Foundation said the Center for Disease Control revised that number in October of 2004 to about one in 9,000 CJD cases per year in the population group age 55 and older.
 
HAVE YOU GOT YOUR CJD QUESTIONNAIRE ASKING REAL QUESTIONS PERTAINING TO ROUTE AND SOURCE OF THE TSE AGENT THAT KILLED YOUR LOVED ONE ???
 
if not, why not...
 
Friday, November 30, 2007
 
CJD QUESTIONNAIRE USA CWRU AND CJD FOUNDATION
 
 
 
Thursday, August 21, 2014
 
FDA Switzerland Reason For Recall Blood product, collected from a donor who was at risk for variant Creutzfeldt-Jakob disease (vCJD), was distributed 2014-05-16
 
 
TSS

Thursday, August 21, 2014

FDA Switzerland Reason For Recall Blood product, collected from a donor who was at risk for variant Creutzfeldt-Jakob disease (vCJD), was distributed 2014-05-16

Reason For Recall Blood product, collected from a donor who was at risk for variant Creutzfeldt-Jakob disease (vCJD), was distributed.

 

Voluntary / Mandated Voluntary: Firm Initiated
Recall Initiation Date 2014-05-16
Initial Firm Notification of Consignee or Public E-Mail
Distribution Pattern Switzerland

 

 


 

 

see more ;

 

Biologics Red Blood Cells Leukocytes Reduced W089813410351; Class II Blood products, collected from a donor who was at risk for variant Creutzfeldt-Jakob disease (vCJD), were distributed. Inova Health Care Services, Inova Blood Donor Services
Biologics Blood and Blood Products for Reprocessing W089813410351; Class III Blood products, collected from a donor who was at risk for variant Creutzfeldt-Jakob disease (vCJD), were distributed. Inova Health Care Services, Inova Blood Donor Services
Biologics Cryoprecipitated AHF W089813410351; Class II Blood products, collected from a donor who was at risk for variant Creutzfeldt-Jakob disease (vCJD), were distributed. Inova Health Care Services, Inova Blood Donor Services
Biologics Red Blood Cells Leukocytes Reduced W088414515528; W088414516606; Class II Blood products, collected from a donor who was at risk for variant Creutzfeldt-Jakob disease (vCJD), were distributed. Blood Bank Of Hawaii

 

 


 

 

Saturday, July 07, 2012

Class II, Blood products, collected from a donor who was at risk for variant Creutzfeldt-Jakob disease ( vCJD) USA

Enforcement Report

http://vcjdtransfusion.blogspot.com/2012/07/class-ii-blood-products-collected-from.html


Monday, June 11, 2012

Guidance for Industry Draft Guidance for Industry: Amendment to “Guidance for Industry: Revised Preventive Measures to Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease and Variant Creutzfeldt-Jakob Disease by Blood and Blood Products”

IN SHORT ;

“However, based on animal studies, as well as on FDA risk assessments, the possibility of vCJD transmission by a U.S.-licensed plasma derivative, while extremely small, cannot be absolutely ruled out. For these reasons, the recommendations for labeling for plasma derivatives will include mention of vCJD for the first time, and the potential risk for its transmission. The recommended elements of the warning label for CJD are unchanged and continue to describe its transmission as a theoretical risk, given that there is no confirmed evidence that CJD is transmitted by blood (Refs. 4-7).“

IN FULL, as follows ;

Monday, June 11, 2012

Guidance for Industry Draft Guidance for Industry: Amendment to “Guidance for Industry: Revised Preventive Measures to Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease and Variant Creutzfeldt-Jakob Disease by Blood and Blood Products”

http://creutzfeldt-jakob-disease.blogspot.com/2012/06/guidance-for-industry-draft-guidance.html



Friday, June 29, 2012

Highly Efficient Prion Transmission by Blood Transfusion

http://transmissiblespongiformencephalopathy.blogspot.com/2012/06/highly-efficient-prion-transmission-by.html



Sunday, June 3, 2012

A new neurological disease in primates inoculated with prion-infected blood or blood components

http://transmissiblespongiformencephalopathy.blogspot.com/2012/06/new-neurological-disease-in-primates.html

 

 

Sunday, March 09, 2014

 

A Creutzfeldt-Jakob Disease (CJD) Lookback Study: Assessing the Risk of Blood Borne Transmission of Classic Forms of Creutzfeldt-Jakob Disease

 

FDA TSEAC CIRCUS AND TRAVELING ROAD SHOW FOR THE TSE PRION DISEASES

 


 

 

Sunday, April 06, 2014

 

SPORADIC CJD and the potential for zoonotic transmission there from, either directly or indirectly via friendly fire iatrogenic mode, evidence to date

 


 

 

Wednesday, December 11, 2013

 

*** Detection of Infectivity in Blood of Persons with Variant and Sporadic Creutzfeldt-Jakob Disease ***

 


 

 

Friday, January 10, 2014

 

vpspr, sgss, sffi, TSE, an iatrogenic by-product of gss, ffi, familial type prion disease, what it ???

 


 

 

Monday, May 19, 2014

 

Variant CJD: 18 years of research and surveillance

 


 

 

Sunday, June 29, 2014

 

Transmissible Spongiform Encephalopathy TSE Prion Disease North America 2014

 


 

 

Tuesday, August 12, 2014

 

*** MAD COW USDA TSE PRION COVER UP or JUST IGNORANCE, for the record AUGUST 2014 ***

 

see history of record of either the biggest cover up of mad cow disease, or one of the biggest blunders of the mad cow debacle, just my opinion of the facts...tss

 


 

 

Monday, June 02, 2014

 

*** Confirmed Human BSE aka mad cow Variant CJD vCJD or nvCJD Case in Texas

 


 

 

Tuesday, April 01, 2014

 

*** Questions linger in U.S. CJD cases 2005, and still do in 2014 ***

 


 

 

Monday, August 18, 2014

 

*** Barriers to Creutzfeldt-Jakob Disease Autopsies, California and the USA

 


 

 

PLEASE REMEMBER ;

 

The Akron, Ohio-based CJD Foundation said the Center for Disease Control revised that number in October of 2004 to about one in 9,000 CJD cases per year in the population group age 55 and older.

 

HAVE YOU GOT YOUR CJD QUESTIONNAIRE ASKING REAL QUESTIONS PERTAINING TO ROUTE AND SOURCE OF THE TSE AGENT THAT KILLED YOUR LOVED ONE ???

 

if not, why not...

 

Friday, November 30, 2007

 

CJD QUESTIONNAIRE USA CWRU AND CJD FOUNDATION

 

 


 


 

 

TSS